The WuXi AppTec bulk cell culture production facility, designed by Sartorius Stedim Biotech (SSB), received an honorable mention in the 2014 Facility of the Year Awards at the annual meeting of International Society for Pharmaceutical Engineering (ISPE) in Las Vegas last week.
The WuXi AppTec bulk cell culture production facility, designed by Sartorius Stedim Biotech (SSB), received an honorable mention in the 2014 Facility of the Year Awards at the annual meeting of International Society for Pharmaceutical Engineering (ISPE) in Las Vegas last week.
WuXi AppTec had to design and build a flexible, cost-effective, multiproduct facility for biologics production in line with cGMP standards for the US, EU, and China within a short timeline.
SSB’s bioprocess design consultant team performed the risk assessments to evaluate the relative impact of traditional versus single-use technologies. It was estimated that WuXi would be able to considerably reduce its timeline by selecting a fully single-use process train, thus decoupling the process design from the facility build. The team carried out process modeling to evaluate equipment sizing and identified opportunities for downsizing utilities and for meeting higher classification room requirements by working with single-use technology.
SSB’s expertise in the design and implementation of fully single-use process trains enabled WuXi to achieve its goal in 18 months and become the first biologics production facility in China to be compliant with cGMP standards for the US, EU, and China.
Source: Sartorius Stedim Biotech
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.